Epstein-Barr Virus Antibody to Viral Capsid Antigen, IgA
Also known as: EBV A
Use
The Epstein-Barr Virus (EBV) Antibody to Viral Capsid Antigen, IgA test is used to aid in the detection and prognosis of nasopharyngeal carcinoma. It is not suitable for diagnosing Epstein-Barr virus infectious mononucleosis. This test measures the IgA antibodies against the viral capsid antigen of EBV, which can play a role in diagnosing certain EBV-related conditions, particularly in the context of nasopharyngeal carcinoma, where EBV is often associated.
Special Instructions
Convalescent specimens must be received within 30 days from the receipt of the acute specimens. Parallel testing is preferred. Specimens need to be marked as 'acute' or 'convalescent' accordingly.
Limitations
This test was developed and characterized by ARUP Laboratories and has not been cleared or approved by the US Food and Drug Administration. It is conducted in a CLIA certified laboratory and is intended for clinical purposes. The test is not suitable for diagnosing infectious mononucleosis. Additionally, results may be affected by grossly hemolytic, icteric, or lipemic specimens and by contaminated or heat-inactivated samples.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 31369-2
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.1 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube.
Storage Instructions
Refrigerated storage is required.
Causes for Rejection
Contaminated or heat-inactivated specimens. Grossly hemolytic, icteric, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 30 days |